after giving informed consent, you are randomly assigned to receive either elafibranor or an identical placebo. the assignment is concealed, so neither you nor the study staff knows which one you receive.

before starting the medication, a series of tests are performed to record your current health status. these may include blood tests, imaging of the liver, and a review of your medical history.

you receive a bottle of film‑coated tablets that look the same for both groups. each tablet contains either 120 mg of elafibranor or no active drug (placebo). the tablets are taken by mouth once each day, with or without food.

take one tablet each day for the entire length of the study, which may last several years. continue the same schedule unless a study doctor advises otherwise.

you attend scheduled clinic visits, typically every few months, to allow the study team to check your health. during each visit, blood samples are taken, and any side effects are recorded.

the study team monitors liver function and other laboratory values at each visit to ensure the medication is safe for you. any concerning results may lead to additional testing or a change in dosing.

the number of tablets you have left is counted at each visit to confirm that you are taking the medication as instructed.

at the end of the study period, you undergo a final set of examinations similar to the baseline assessments. the study medication is stopped, and you receive a summary of the study findings that pertain to your participation.